ArticleClinical & experimental ophthalmology2026

Switching to Faricimab or High-Dose Aflibercept for Neovascular AMD in High-Demand Patients: Impact on Injection Interval in a Real-World Cohort.

Zachary George Angus et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.